IP Library Granted Patent US 8,124,134
Granted Patent B2
US 8,124,134 · App. 11/457,388 · Granted Feb 28, 2012

Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from

Assignee: Unigen, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,134
App. No.
11/457,388
Granted
Feb 28, 2012
Kind
B2
Abstract

The present invention provides a novel method for simultaneously inhibiting the cyclooxygenase COX-2 and 5-lipoxygenase (5-LO) enzymes. The method for the simultaneous dual inhibition of COX-2 and 5-LO is comprised of administering a composition containing an individual and/or a mixture of multiple flavans isolated from a single plant or multiple plants in the Acacia genus of plants to a host in need thereof. The present also includes novel methods for the prevention and treatment of COX-2 and 5-LO mediated diseases and conditions. The method for preventing and treating COX-2 and 5-LO mediated diseases and conditions is comprised of administering to a host in need thereof an effective amount of a composition comprising an individual and/or a mixture of multiple flavans isolated from a single plant or multiple plants in the Acacia genus of plants and a pharmaceutically acceptable carrier. The present invention includes a method for isolating and purifying a composition of flavans having dual specificity for COX-2 and 5-LO from the Acacia genus of plants.

Claims (16)

1. A method for treating a cyclooxygenase (COX) and 5-lipoxygenase (5-LO) mediated inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a partially purified plant extract extracted from Acacia wherein said extract is enriched for flavans, wherein the major active ingredients in said extract are catechin and epicatechin.

2. The method of claim 1 wherein said Acacia is selected from the group consisting of Acacia catechu, Acacia concinna, Acacia framesiana, Acacia Senegal, Acacia speciosa, Acacia arabica, Acacia caesia, Acacia pennata, Acacia sinuata, Acacia mearnsii, Acacia picnantha, Acacia dealbata, Acacia auriculiformis, Acacia holoserecia and Acacia mangium.

3. The method of claim 1 wherein said extract is from a plant part selected from the group consisting of stems, stem barks, trunks, trunk barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers, and leaves.

4. The method of claim 1 wherein the COX and 5-LO mediated inflammatory condition is selected from the group consisting of inflammation associated with osteoarthritis, menstrual cramps, Systemic Lupus Erythromatosis, psoriasis, chronic tension headache, migraine headaches, inflammatory bowel disease, minor abrasions, sunburn, contact dermatitis and solid cancers.

5. The method of claim 1 wherein the extract is comprised of 0.01% to 100% of flavans.

6. The method of claim 1 wherein the extract is administered in a dosage selected from 0.01 to 200 mg/kg of body weight.

7. The method of claim 1 wherein the routes of the administration are selected from the group consisting of oral, topical, suppository, intravenous, and intradermic, intragaster, intramusclar, intraperitoneal and intravenous administration in an appropriate pharmaceutical formula.

8. A method for treating aches and pain resulting from a cyclooxygenase (COX) and 5-lipoxygenase (5-LO) mediated inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of a partially purified plant extract extracted from Acacia wherein said extract is enriched for flavans, wherein the major active ingredients in said extract are catechin and epicatechin.

9. The method of claim 8 wherein said plant is selected from the group consisting of the Acacia catechu, Acacia concinna, Acacia framesiana, Acacia Senegal, Acacia speciosa, Acacia arabica, Acacia caesia, Acacia pennata, Acacia sinuata, Acacia mearnsii, Acacia picnantha, Acacia dealbata, Acacia auriculiformis, Acacia holoserecia and Acacia mangium.

10. The method of claim 8 wherein said extract is from a plant part selected from the group consisting of stems, stem barks, trunks, trunk barks, twigs, tubers, roots, root barks, young shoots, seeds, rhizomes, flowers, and leaves.

11. The method of claim 8 wherein the COX and 5-LO mediated inflammatory condition is selected from the group consisting of inflammation associated with osteoarthritis, menstrual cramps, Systemic Lupus Erythromatosis, psoriasis, chronic tension headache, migraine headaches, inflammatory bowel disease, minor abrasions, sunburn, contact dermatitis and solid cancers.

12. The method of claim 8 wherein the extract is comprised of 0.01% to 100% of flavans.

13. The method of claim 8 wherein the extract is administered in a dosage selected from 0.01 to 200 mg/kg of body weight.

14. The method of claim 8 wherein the routes of the administration are selected from the group consisting of oral, topical, suppository, intravenous, and intradermic, intragaster, intramusclar, intraperitoneal and intravenous administration in an appropriate pharmaceutical formula.

15. The method of claim 1 wherein said extract is comprised of at least 14.83% catechin/epicatechin.

16. The method of claim 8 wherein said extract is comprised of at least 14.83% catechin/epicatechin.

Assignments (2)
CHANGE OF NAME Recorded Oct 4, 2011
From: UNIGEN PHARMACEUTICALS, INC.
To: UNIGEN, INC.
Reel/Frame 027015/0720 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2006
From: JIA, QI; NICOLS, TIMOTHY C.; RHODEN, ERIC E.; WAITE, SCOTT
To: UNIGEN PHARMACEUTICALS, INC.
Reel/Frame 018043/0366 →
Continuity (2)
Continuation 10104477 · Mar 22, 2002
Related Publication 20060269627A1 · Nov 30, 2006